Literature DB >> 8582436

Pharmacokinetics of lidocaine and its major metabolite- monoethylglycinexylidide (MEGX) in rabbits with experimental common bile duct obstruction.

J Wójcicki1, T Sulikowski, M Wójcicki, M Droździk, B Gawrońska-Szklarz, B Barcew-Wiszniewska, J Skowron, L Rózewicka, U Gołdyn.   

Abstract

The aim of this study was to evaluate, using an experimental model, the effect of obstructive cholestasis on the pharmacokinetics of lidocaine and the formation rate of its major metabolite- monoethylglycinexylidide (MEGX)-in rabbits. The investigation was carried out on 20 rabbits, randomly divided into two groups: a control one sham-operated and an experimental one-animals with biliary duct ligation. The measurements, i.e. laboratory and pharmacodynamic tests, as well as pharmacokinetic assays were performed prior to the operation as well as 10-12 days after the bile duct ligation. At the end stage of the study, livers were examined macro- and microscopically and biochemical analysis of the liver microsomes were performed. Lidocaine was given intravenously, as a bolus of 6 mg/kg. Blood for pharmacokinetic assay was sampled within 6 h following the drug administration, and MEGX concentration was evaluated 15 min after lidocaine had been administered. The immunofluorescence polarization method was employed for determination of lidocaine and MEGX concentrations. The one-compartment open model was used for calculations.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8582436     DOI: 10.1007/BF03226365

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  16 in total

1.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

2.  Phosphorus assay in column chromatography.

Authors:  G R BARTLETT
Journal:  J Biol Chem       Date:  1959-03       Impact factor: 5.157

3.  Normal antipyrine metabolism in patients with cholesterol cholelithiasis. Evidence that the disease is not due to generalized hepatic microsomal dysfunction.

Authors:  G W Hepner; E S Vesell
Journal:  Am J Dig Dis       Date:  1975-01

4.  Aminopyrine metabolism in the presence of hyperbilirubinemia due to cholestasis or hepatocellular disease. Combined use of laboratory tests to study disease-induced alterations in drug disposition.

Authors:  G W Hepner; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1977-05       Impact factor: 6.875

5.  Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans.

Authors:  P D Thomson; K L Melmon; J A Richardson; K Cohn; W Steinbrunn; R Cudihee; M Rowland
Journal:  Ann Intern Med       Date:  1973-04       Impact factor: 25.391

6.  Evaluation of quantitative liver function tests in liver donors.

Authors:  M Burdelski; M Oellerich; P Lamesch; E Raude; B Ringe; P Neuhaus; S Bortfeld; C Kämmerling; H Raith; M Scheruhn
Journal:  Transplant Proc       Date:  1987-10       Impact factor: 1.066

7.  Lidocaine metabolism in human liver microsomes by cytochrome P450IIIA4.

Authors:  M J Bargetzi; T Aoyama; F J Gonzalez; U A Meyer
Journal:  Clin Pharmacol Ther       Date:  1989-11       Impact factor: 6.875

8.  Assessment of lidocaine metabolite formation in comparison with other quantitative liver function tests.

Authors:  B Meyer-Wyss; E Renner; H Luo; A Scholer
Journal:  J Hepatol       Date:  1993-08       Impact factor: 25.083

9.  Monoethylglycinexylidide formation kinetics: a novel approach to assessment of liver function.

Authors:  M Oellerich; E Raude; M Burdelski; M Schulz; F W Schmidt; B Ringe; P Lamesch; R Pichlmayr; H Raith; M Scheruhn
Journal:  J Clin Chem Clin Biochem       Date:  1987-12

10.  Evaluation of the liver function of cirrhotic patients based on the formation of monoethylglycine xylidide (MEGX) from lidocaine.

Authors:  M Schinella; A Guglielmi; G F Veraldi; M Boni; M Frameglia; M Caputo
Journal:  Eur J Clin Chem Clin Biochem       Date:  1993-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.